

Attorney Docket No.: DC-0153
Inventors: Guyre et al.
Serial No.: 09/817,950
Filing Date: March 27, 2001
Page 2

In the Specification:

At page 4, lines 14-30, please replace the paragraph with the following rewritten paragraph:

Q1 ~~MM~~ Previous studies using mAbs RM3/1, Ber-Mac3 and others have reported that only 0%-40% of circulating monocytes are positive for CD163 (Hogger, P. et al. 1998. *Pharm Res.* 15:296-302; Hogger et al. 1998. *J. Immunol.* 161:1883-1890; Zwadlo, G. et al. 1987. *Exp. Cell Biol.* 55:295-304; Backe, E. et al. 1991. *J. Clin. Path.* 44:936-945; van den Heuvel, M. et al. 1999. *J. Leuk. Biol.* 66:858-866). However, previous studies with another antibody to p155, a molecule that has been shown to be identical to CD163, Mac 2-48, has consistently demonstrated that virtually all freshly isolated monocytes are positive for CD163. To address the possibility that sub-optimal detection of the lower affinity RM3/1 and Ber-Mac3 antibodies (previously used only with FITC labeled secondary antibodies) might account for this discrepancy, freshly isolated PBMCs were stained with FITC conjugated AML 2.23 (anti-CD14) and biotinylated RM3/1 or biotinylated Mac2-48, followed by detection with SAPE~~MM~~-

Attorney Docket No.: DC-0153
Inventors: Guyre et al.
Serial No.: 09/817,950
Filing Date: March 27, 2001
Page 3

At page 8, lines 33-35 and page 9, lines 1-9, please replace the paragraph with the following rewritten paragraph:

a2 ~~¶~~The dose response curve for the IL-10 effect on CD163 expression demonstrates a dynamic range of IL-10 concentrations that is from 0.1 ng/ml to 10 ng/ml. This is consistent with previous findings concerning the effect of IL-10 on a wide range of monocyte functions such as tissue factor expression and associated procoagulant activity (Ernofsson, M. et al. 1996. *Br. J. Haematol.* 95:249-257; Osnes, L.T. et al. 1996. *Cytokine* 8:822-827), as well as MIP-1 α (Berkman, N. et al. 1995. *J. Immunol.* 155:4412-4418), metalloproteinase (Lacraz, S. et al. 1992. *J. Clin. Invest.* 90:382-388) and TNF receptor (Hart, P.H. et al. 1996. *J. Immunol.* 157:3672-3680) expression. ~~¶~~

At page 12, lines 32-33 and page 13, lines 1-7, please replace the paragraph with the following rewritten paragraph:

a3 ~~¶~~For cytokine treatment studies, isolated PBMCs were suspended in hepes buffered RPMI 1640/0.05% gentamicin/10% FBS at a concentration of 2.0×10^6 to 2.5×10^6 cells/ml and cultured in 96 well plates at 37°C and 5% CO₂ in the presence of various mediators such as IL-10. Mononuclear cells were stained for flow